U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H20N2O2
Molecular Weight 248.3208
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PINDOLOL

SMILES

CC(C)NCC(O)COC1=CC=CC2=C1C=CN2

InChI

InChIKey=JZQKKSLKJUAGIC-UHFFFAOYSA-N
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/2879589 http://www.ncbi.nlm.nih.gov/pubmed/6125094 https://www.ncbi.nlm.nih.gov/pubmed/9536453 https://www.ncbi.nlm.nih.gov/pubmed/2429847 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf

Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. The partial beta-adrenergic agonistic activity of pindolol in the heart appears to be completely restricted to the sinoatrial pacemaker. In standard pharmacologic tests in man and animals, Pindolol attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. In addition to beta-adrenergic activity pindolol demonstrates mixed agonist-antagonist activity at central 5-HT receptors. Although in accordance with the hypothesis that pindolol increases the antidepressant effects of selective serotonin reuptake inhibitors by antagonism of 5-HT at inhibitory 5-HT1A autoreceptors, pindolol possesses partial agonist activity at 5-HT1A receptors. Pindolol tablets are indicated in the management of hypertension.

CNS Activity

Originator

Sandoz
40
Sources: Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. Takuji Hara. Edward Elgar Publishing, 2003. ISBN 1843760509 p.76

Approval Year

1982
100
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 6.4 nM [Ki]
Antagonist
2778
 9.25 null [pKd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
VISKEN

Approved Use

Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.

Launch Date

1982
Primary
Approved
8429
PINDOLOL

Approved Use

Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
250 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2880722/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1200 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2880722/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2880722/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Other AEs: Bizarre dreams, Dizziness...
Other AEs:
Bizarre dreams (5%)
Dizziness (9%)
Fatigue (8%)
Hallucinations (<1%)
Insomnia (10%)
Nervousness (7%)
Weakness (4%)
Paresthesia (3%)
Dyspnea (5%)
Edema (6%)
Heart failure (<1%)
Palpitations (<1%)
Chest pain (3%)
Joint pain (7%)
Muscle cramps (3%)
Muscle pain (10%)
Abdominal discomfort (4%)
Nausea (5%)
Pruritus (1%)
Rash (<1%)
Anxiety (uncertain, <2%)
Lethargy (uncertain, <2%)
Visual disturbances (uncertain, <2%)
Hyperhidrosis (uncertain, <2%)
Bradycardia (uncertain, <2%)
Claudication (uncertain, <2%)
Cold extremities (uncertain, <2%)
Heart block (uncertain, <2%)
Syncope (uncertain, <2%)
Tachycardia (uncertain, <2%)
Weight gain (uncertain, <2%)
Hypotension (uncertain, <2%)
Diarrhea (uncertain, <2%)
Vomiting (uncertain, <2%)
Wheezing (uncertain, <2%)
Impotence (uncertain, <2%)
Pollakiuria (uncertain, <2%)
Eye discomfort (uncertain, <2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Pruritus 1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Insomnia 10%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Muscle pain 10%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Chest pain 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Muscle cramps 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Paresthesia 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Abdominal discomfort 4%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Weakness 4%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Bizarre dreams 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Dyspnea 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Nausea 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Edema 6%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Joint pain 7%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Nervousness 7%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Fatigue 8%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Dizziness 9%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Hallucinations <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Heart failure <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Palpitations <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Rash <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Anxiety uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Bradycardia uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Claudication uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Cold extremities uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Diarrhea uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Eye discomfort uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Heart block uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Hyperhidrosis uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Hypotension uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Impotence uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Lethargy uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Pollakiuria uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Syncope uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Tachycardia uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Visual disturbances uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Vomiting uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Weight gain uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Wheezing uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1852

substrate
1217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1537

CYP
270

OCT transporters
1

MATE proteins
1
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1891
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1217
 yes
P-gp
1537
 yes
CYP
270
 yes
yes (co-administration study)
Comment: cimetidine coadministration increases pindolol plasma levels
MATE proteins
1
 yes
yes (co-administration study)
Comment: cimetidine increased AUC by 1.4 fold and Cmax by 1.3 fold
OCT transporters
1
 yes
yes (co-administration study)
Comment: cimetidine increased AUC by 1.4 fold and Cmax by 1.3 fold
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8214
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8214
ChemicalBook
CB3105373
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3105373
MolPort
MolPort-001-792-503
https://www.molport.com/shop/molecule-link/MolPort-001-792-503
eMolecules
494631
https://www.emolecules.com/cgi-bin/more?vid=494631
PubMed

PubMed

TitleDatePubMed
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion.
1975 Jul
Partial agonistic properties of (+/-)-pindolol at atypical beta-adrenoceptors in the guinea pig gastric fundus.
2001
Flesinoxan, a 5-HT1A receptor agonist/alpha 1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits.
2001 Aug
Further characterization of beta3-adrenoceptors in the guinea pig gastric fundus: stereoselectivity, beta-adrenoceptor alkylation, and structure-activity relationship.
2001 Dec
Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low.
2001 Dec
Imaging of beta-adrenoceptors in the human thorax using (S)-[(11)C]CGP12388 and positron emission tomography.
2001 Dec 21
Influence of various biological matrices (plasma, blood microdialysate) on chromatographic performance in the determination of beta-blockers using an alkyl-diol silica precolumn for sample clean-up.
2001 Dec 25
No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors.
2001 Nov 30
Management of treatment-refractory panic disorder.
2001 Spring
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
2002 Apr
Direct determination of pindolol enantiomers in human serum by column-switching LC-MS/MS using a phenylcarbamate-beta-cyclodextrin chiral column.
2002 Apr 1
[Pharmacology of beta blockers and their significance for therapy of hypertension].
2002 Aug
[Reactions between dialkylamine drugs, 2,3-dichloro-1,4-naphthoquinone and acetaldehyde].
2002 Aug
Serotonergic control of cerebellar mossy fiber activity by modulation of signal transfer by rat pontine nuclei neurons.
2002 Aug
Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension.
2002 Aug
Melatonin potentiates 5-HT(1A) receptor activation in rat hypothalamus and results in hypothermia.
2002 Aug
Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine.
2002 Aug
Indorenate produces antidepressant-like actions in the rat forced swimming test via 5-HT1A receptors.
2002 Dec
The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.
2002 Dec
Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor.
2002 Dec 15
Screening drugs for metabolic stability using pulsed ultrafiltration mass spectrometry.
2002 Feb
Studies on the expression and function of beta-3-adrenoceptors in the colon of rats with acetic acid-induced colitis.
2002 Feb
Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET.
2002 Feb
Methiothepin attenuates gastric secretion and motility effects of vagal stimulants at the dorsal vagal complex.
2002 Feb 1
Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium.
2002 Jan
PET-examination and metabolite evaluation in monkey of [(11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor.
2002 Jan
Imaging the neurochemical brain in health and disease.
2002 Jan-Feb
Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice.
2002 Jul
Synthesis and evaluation of (S)-[18F]-fluoroethylcarazolol for in vivo beta-adrenoceptor imaging in the brain.
2002 Jul
The neuropharmacology of serotonin and noradrenaline in depression.
2002 Jun
[Effect of (+/-)-pindolol on the central 5-HT1A receptor by the use of in vivo microdialysis and hippocampal slice preparations].
2002 Jun
Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy.
2002 Jun
5-HT1A receptor blockade and the motivational profile of ethanol.
2002 Jun 28
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
2002 Mar
Pharmacokinetic scaling of pindolol in healthy volunteers after single dose oral administration.
2002 Mar
Copper(II) complexes of the beta-blocker pindolol: properties, structure, biological activity.
2002 Mar
Somatodendritic action of pindolol to attenuate the paroxetine-induced decrease in serotonin release from the rat ventral hippocampus: a microdialysis study.
2002 May
Determination of bopindolol in pharmaceuticals by capillary isotachophoresis.
2002 May 15
Simultaneous determination of eight beta-blockers by gradient high-performance liquid chromatography with combined ultraviolet and fluorescence detection in corneal permeability studies in vitro.
2002 May 25
Familial left ventricular hypertrabeculation in two blind brothers.
2002 May-Jun
Involvement of 5-HT7 receptors in serotonergic effects on spike afterpotentials in presumed jaw-closing motoneurons of rats.
2002 Nov 8
Spin trapping study of reactive oxygen species formation during bopindolol peroxidation.
2002 Oct 15
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
2002 Sep
Pharmacological management for agitation and aggression in people with acquired brain injury.
2003
Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta.
2003 Jan
Evidence that the anorexia induced by lipopolysaccharide is mediated by the 5-HT2C receptor.
2003 Jan
Chiral separation of amines with N-benzoxycarbonylglycyl-L-proline as selector in non-aqueous capillary electrophoresis using methanol and 1,2-dichloroethane in the background electrolyte.
2003 Jan 17
EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans.
2003 Mar
Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers.
2003 Mar
Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice.
2003 Mar 19
Patents

Patents

20010003749
8
JP1031715A
6
JP2002511777A
414
JP2009530408A
51
JP4527404B2
7
JPH02237913A
1
JPS5511543A
1
JPS55151557A
1
JPS5576859A
1
JPS56140970A
1
JPS5659772A
1
JPS5683471A
1
JPS57142970A
1
JPS57142971A
1
JPS5724376A
1
JPS5813566A
1
JPS59144757A
2
JPS5927869A
2
JPS6124517A
1
JPS6193113A
1

Sample Use Guides

In Vivo Use Guide
The recommended initial dose of pindolol tablets is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3 to 4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Pindolol (1-10 uM) blocked the catecholamine-induced augmentation of late after-discharge (LAD) (postganglionic branches or ganglion cells of the paravertebral sympathetic chain of the bullfrog were used in vitro)
Name Type Language
PINDOLOL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NSC-757276
Code English
4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE
Systematic Name English
PINDOLOL COMPONENT OF VISKAZIDE
Common Name English
PINDOLOL [JAN]
Common Name English
PECTOBLOC
Brand Name English
DL-LB-46
Common Name English
(RS)-PINDOLOL
Common Name English
DL-PINDOLOL
Common Name English
2-PROPANOL, 1-(1H-INDOL-4-YLOXY)-3-(1-METHYLETHYL)AMINO-
Systematic Name English
PINDOLOL [MI]
Common Name English
PYNASTIN
Common Name English
PINDOLOL [HSDB]
Common Name English
PINDOLOL [EP MONOGRAPH]
Common Name English
PINDOLOL [USAN]
Common Name English
LB-46
Code English
DECRETEN
Common Name English
4-(3-ISOPROPYLAMINO-2-HYDROXYPROPOXY)INDOLE
Systematic Name English
VISKAZIDE COMPONENT PINDOLOL
Common Name English
1-((1-METHYLETHYL)AMINO)-3-(4-INDOLYLOXY)-2-PROPANOL
Systematic Name English
CARVISKEN
Brand Name English
PINDOLOL [VANDF]
Common Name English
PINBETOL
Common Name English
(±)-PINDOLOL
Common Name English
PRINODOLOL
Common Name English
1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol
Systematic Name English
PINDOLOL [USP MONOGRAPH]
Common Name English
CALVISKEN
Brand Name English
PINDOLOL [MART.]
Common Name English
GLAUCO-VISKEN
Common Name English
APO-PINDOL
Common Name English
BLOCKLIN-L
Brand Name English
N-(2-HYDROXY-3-(1H-INDOL-4-YLOXY)PROPYL)-N-ISOPROPYLAMINE
Systematic Name English
PINDOLOL [USP-RS]
Common Name English
pindolol [INN]
Common Name English
PINDOLOL [ORANGE BOOK]
Common Name English
DL-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE
Common Name English
Pindolol [WHO-DD]
Common Name English
(±)-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE
Systematic Name English
DURAPINDOL
Common Name English
VISKEN
Brand Name English
BETAPINDOL
Common Name English
(±)-LB-46
Code English
2-PROPANOL, 1-(INDOL-4-YLOXY)-3-(ISOPROPYLAMINO)-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC07AA03
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
LIVERTOX NBK548489
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
NCI_THESAURUS C29576
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
NDF-RT N0000000161
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
WHO-VATC QC07CA03
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
WHO-ATC C07CA03
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
NDF-RT N0000175556
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
WHO-ATC C07AA03
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
Code System Code Type Description
FDA UNII
BJ4HF6IU1D
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
RXCUI
8332
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY RxNorm
CHEBI
8214
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
DRUG BANK
DB00960
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
MESH
D010869
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023476
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
DRUG CENTRAL
2176
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
INN
2698
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
MERCK INDEX
m8824
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY Merck Index
LACTMED
Pindolol
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
NCI_THESAURUS
C47673
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
HSDB
6539
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
SMS_ID
100000092294
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
WIKIPEDIA
PINDOLOL
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
ECHA (EC/EINECS)
236-867-9
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
ChEMBL
CHEMBL500
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
PUBCHEM
4828
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
CAS
13523-86-9
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
EVMPD
SUB09854MIG
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
DAILYMED
BJ4HF6IU1D
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
IUPHAR
91
Created by admin on Fri Dec 15 19:00:27 GMT 2023 , Edited by admin on Fri Dec 15 19:00:27 GMT 2023
PRIMARY
NSC
757276
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
RS_ITEM_NUM
1539701
Created by admin on Fri Dec 15 19:00:28 GMT 2023 , Edited by admin on Fri Dec 15 19:00:28 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PINDOLOL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966